The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I guess this is about the third q&a that he's done recently , more if you add that Finnish Investor TV one .
Biggest question always - How is this getting funded for the future ?
But he can't answer it (publicly) as whatever it is ,its not completed ( or more likely the option to go for has not been chosen)
We've had this great data set from P1/2 , which hints that this could be a lot bigger deal than first hoped .
But at present , Faron don't have ALL the data they need to make the right choice . The findings they come up with from these patients will steer the direction . The biomarkers to see which patient groups will be best targeted , the soluble clever 1 reaction from increased dosing . They need to know this before deciding on what to push for with the FDA . Markku even turned one question around regarding if all 5 cohorts will be taken to P3 . Nothing is decided yet until they have the whole picture .
Frustrating and disappointing . Yes . For us .
But stepping back , we have this amazing patented potential cancer therapy that ( using the analogy of my other share GGP ) is a discovery that can't have a value put on it yet as they haven't found the edges of it . Every new result ends up putting another zero on the potential price .
I know a bird in the hand is worth 2 in the bush , but we might as well let them get on with developing Bex in the way that will benefit us most in the long term .
Having said all that , I too was left wondering exactly what the point of todays webinar was though . I guess it just covered the basics , but it sure wasn't a sales pitch for new investors .
We were all riding high on the back of Thurdays forum .
I was hoping for Markku to put this discovery into some context - to show us how big it is .
Lets just see what comes next now .
Dan , yes I think he did - Q4 could turn up some real value findings - biomarkers and soluble dosing for starters .
Did I hear Markku correctly, does he think we will be able to identify responders pre treatment before the end of the year?
If that is what he said this is massive!
I agree. He was very nervous and he couldn't answer the questions. I"m disappointed. This was the first time, when I really thought that I did mistake when I bought so much Faron. I hope that I"m wrong. Maybe that USA case will show us something better news.
For the first time since I Invested some years ago ... feeling a bit deflated.
Not the best Webinar I have seen.
Poor Q&A with just a few questions asked and answered with no real difficult questions asked.
From the proactive interview, anyone know why Marku is off to the US this week?
Welcome onboard Savvy , yes we are starting to get into the nitty gritty now .
I guess Markku can't answer the funding question , however many times we ask .
But yes , I don't see another simple placing for £15m coming again .
Once they have more data on soluble and biomarkers , they will have an even stronger hand hopefully , and also a clearer picture of what path top take next . Discussions with FDA won't happen till Q1 2022 , so we have next quarter to do some data crunching , and see where we are .
They got EIC & Business Finland involvement , and super soft open ended loans a few months ago based on the data they had . The data today is even stronger , and by Q4 may be even better again .
Who knows , by end of Q4 we may have a HIBISCUS top line data , there's your funding sorted in one go !
Either way , the funding going forward will only come if its right for Faron ,and in itself will mean we get moved further down the line towards commercialisation , which is what we are all here for in the end .
Anytime funding is mentioned it seems like they are working on something.. Not a basic fundraise/dilution/hand in cap to investors.
I reckon its either financing or a large investor buying in
Long time lurker here. Good to see the data presented at ESMO with the details behind the 5 tumour types prioritised for MATINS Part3. What I found most informative was the granularity for the first time on the clinical benefit rate/disease control rate, with breakdown between cases of stable disease and partial response (latter normally defined by RECIST criteria as >30% tumour shrinkage). Here the announcement of only 1 partial response across the entire Part 2 study pts was perhaps a little disappointing (and maybe consistent with what seems to be a fairly muted post-ESMO reaction), although as Marku has consistently emphasised these are heavily pre-treated patient populations. Also seems we may have to wait a little longer to define the optimal dose/schedule given this was focused on colorectal cancer pts where benefit overall was lower than hoped, but good to see they have already moved onto more responsive tumour types to get that information ASAP. Here hoping that the biomarker work over the next 3 months or so will also provide more guidance to support the discussions with the regulatory agencies on next study design. In summary, still reasons to believe, just need to remain patient…
I asked two questions about funding and dosing , but neither made through .
Even the Peel Hunt guy asked about Soluble , told to expect some data in the fourth quarter .
Lots of data for them to work through - biomarkers etc , looks like increased dosing frequency may be running on these patients now -
Wasn't giving much else away etc about funding , although did say he would let us know when it is 'completed' . Sounds like they are working on something already .
I guess we have to stay patient , wait for Faron to tell us the news as it comes through .
But either way - you get the feeling they are very happy with what they have , and now have lots to sift through to help improve the focus on the next move .
Marku believes they are in the strongest position ever with bex and they can really help cancer paitents